Clinical Trial Update: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled trial evaluating sevelamer carbonate for hyperphosphatemia in non-dialysis chronic kidney disease patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• SEVELAMER CARBONATE (sevelamer carbonate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Chronic Kidney Disease, Hyperphosphatemia | Phase 3 | Status: TERMINATED